PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Fate Therapeutics, Inc.

USPTO PatentsView assignee record - 47 granted patents across 8 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Fate ranks #7,002 of 50,000 tracked US assignees by granted-patent volume, with 47 patents across 8 technology areas.

#7,002
of 50,000 US assignees by volume
Top 34%
by Innovation Score (41.2/100)
21.4
avg claims per patent
+160%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7002 · US Corporation #7,002 · 47 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 47 grants
  • UPPER-Q #7,002/50,000
  • PHOTO-FINISH Delta Int'l (Singapo…
  • CPC-NARROW C12N · 8 areas
  • INNOV-PAR 41.2/100
  • CLAIMS-DENSE 21.4 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +160% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Delta Electronics Int'l (singapore) Pte Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Fate

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Fate Therapeutics, Inc. stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-NARROW, INNOV-PAR, CLAIMS-DENSE, TYPE-USCORP, VEL-SURGE, BOOK-FULL. Volume places it #7,002 of 50,000; Innovation Score 41.2/100 sits in the top 34% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Delta Electronics Int'l (singapore) Pte Ltd (±0 grants).

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Portfolio overview

Fate Therapeutics, Inc. has been granted 47 US utility patents between 2016 and 2025, placing Fate Therapeutics, Inc. at #7,002 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.4 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Fate Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Fate sits between Delta Electronics Int'l (singapore) Pte Ltd (47 patents, rank #6,998) and Guangzhou Issyzone Technology Co., Limited (47 patents, rank #7,006) - the closest US assignees by grant volume. The composite Innovation Score of 41.2/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 26 grants, compared with 10 in the 2015–2019 window, a +160% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Fate Therapeutics, Inc.'s 21.4 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 8 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Fate's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Fate holds 47 patents at rank #7,002, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Fate

By rank, the assignees closest to #7,002 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Fate's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Fate, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (41 here).

Extrahop Networks, Inc. 41 PN II, Inc. 41 NEW Century Products Co., Ltd. 41 Honeybee Robotics, Llc 41

Fate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

051015 2016201720182019202020212022202320242025 11
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Fate Therapeutics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 3 6.4%
2017 1 2.1%
2018 4 8.5%
2019 2 4.3%
2020 4 8.5%
2021 10 21.3%
2022 5 10.6%
2023 3 6.4%
2024 4 8.5%
2025partial year 11 23.4%

Which technologies does Fate Therapeutics, Inc. patent most?

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#7,002

of 50,000 tracked assignees

Innovation Score

41.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.